

| OMB APPROVAL             |                     |
|--------------------------|---------------------|
| OMB Number:              | 3235-0287           |
| Estimated average burden | hours per response: |
|                          | 0.5                 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |  |  |
|--|--|--|
| 1. Name and Address of Reporting Person*<br><u>Arix Bioscience plc</u><br>_____<br>(Last) (First) (Middle)<br>20 BERKELEY SQUARE<br>_____<br>(Street)<br>MAYFAIR, X0 W1J6EQ<br>LONDON<br>_____<br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>LogicBio Therapeutics, Inc. [ LOGC ]</u> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director <input checked="" type="checkbox"/> 10% Owner<br>Officer (give title below) Other (specify below) |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br>07/16/2020                             |  |
| 4. If Amendment, Date of Original Filed (Month/Day/Year)   |  |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                          | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------------------------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                    |   |  |   |
| Common stock                    | 07/16/2020                           |  | S                              |   | 16,332  | D          | \$8.559 <sup>(1)</sup>   | 2,962,691   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 07/17/2020                           |  | S                              |   | 31,101  | D          | \$9.24 <sup>(3)</sup>    | 2,931,590   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 07/20/2020                           |  | S                              |   | 36,983  | D          | \$9.249 <sup>(4)</sup>   | 2,894,607   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 07/22/2020                           |  | S                              |   | 22,651  | D          | \$9.004 <sup>(5)</sup>   | 2,871,956   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 07/29/2020                           |  | S                              |   | 2,709   | D          | \$8.781 <sup>(6)</sup>   | 2,869,247   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 08/12/2020                           |  | S                              |   | 1,335   | D          | \$8.79 <sup>(7)</sup>    | 2,867,912   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 08/13/2020                           |  | S                              |   | 159   | D          | \$8.75                   | 2,867,753   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 09/24/2020                           |  | S                              |   | 38,514  | D          | \$7.629 <sup>(8)</sup>   | 2,829,239   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 09/25/2020                           |  | S                              |   | 174,219   | D          | \$7.077 <sup>(9)</sup>   | 2,655,020   | I  | See footnote <sup>(2)</sup>                           |
| Common stock                    | 09/28/2020                           |  | S                              |   | 273,584   | D          | \$7.5365 <sup>(10)</sup> | 2,381,436   | I  | See footnote <sup>(2)</sup>                           |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date |   |  |  |   |  |

|   |
|---|
| 1. Name and Address of Reporting Person*<br><u>Arix Bioscience plc</u><br>_____<br>(Last) (First) (Middle)<br>20 BERKELEY SQUARE<br>_____<br>(Street) |
|---|

|  |         |          |
|--|---------|----------|
| MAYFAIR,<br>LONDON                           | X0      | W1J6EQ   |
| (City)                                       | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*     |         |          |
| <a href="#">Arix Bioscience Holdings Ltd</a> |         |          |
| (Last)                                       | (First) | (Middle) |
| 20 BERKLEY SQUARE                            |         |          |
| (Street)                                     |         |          |
| MAYFAIR,<br>LONDON                           | X0      | W1J6EQ   |
| (City)                                       | (State) | (Zip)    |

**Explanation of Responses:**

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$8.50 to \$8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.
2. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.
3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$9.10 to \$9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
4. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$9.10 to \$9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
5. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$9.00 to \$9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
6. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$8.75 to \$8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
7. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$8.75 to \$8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
8. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$7.35 to \$7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
9. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$7.00 to \$8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
10. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$7.40 to \$7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

**Remarks:**

[Arix Bioscience Plc, by: /s/  
Marcus Karia, Authorized  
Officer](#) [10/05/2020](#)

[Arix Bioscience Holdings  
Limited, by: /s/ Marcus Karia,  
Authorized Officer](#) [10/05/2020](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**